Abstract
The most common complication of permanent vascular access is thrombosis, which accounts for 80 to 85% of AV access loss. Treatment of venous stenosis by percutaneous angioplasty, endovascular stents and surgical revision is clinically important but many strategies to prevent thrombosis have been employed, such as antiplatelet agents, systemic anticoagulation, and experimental therapies as fish oils, heparinoids, clopidogrel, renin-angiotensin system antagonists, calcium channel blockers, alpha adrenergic antagonists, homocysteine-lowering agents and beta-hydroxybetamethyglutaryl coenzyme-A reductase inhibitors. Future but promising approaches are endovascular radiation and gene therapy.
| Original language | English |
|---|---|
| Pages (from-to) | 280-285 |
| Number of pages | 6 |
| Journal | Journal of Nephrology |
| Volume | 19 |
| Issue number | 3 |
| Publication status | Published - May 2006 |
Fingerprint
ASJC Scopus subject areas
- Nephrology
Cite this
Vascular access-related thrombotic complications : Research hypotheses and therapeutic strategies. / Bruno, Simona; Remuzzi, G.
In: Journal of Nephrology, Vol. 19, No. 3, 05.2006, p. 280-285.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Vascular access-related thrombotic complications
T2 - Research hypotheses and therapeutic strategies
AU - Bruno, Simona
AU - Remuzzi, G.
PY - 2006/5
Y1 - 2006/5
N2 - The most common complication of permanent vascular access is thrombosis, which accounts for 80 to 85% of AV access loss. Treatment of venous stenosis by percutaneous angioplasty, endovascular stents and surgical revision is clinically important but many strategies to prevent thrombosis have been employed, such as antiplatelet agents, systemic anticoagulation, and experimental therapies as fish oils, heparinoids, clopidogrel, renin-angiotensin system antagonists, calcium channel blockers, alpha adrenergic antagonists, homocysteine-lowering agents and beta-hydroxybetamethyglutaryl coenzyme-A reductase inhibitors. Future but promising approaches are endovascular radiation and gene therapy.
AB - The most common complication of permanent vascular access is thrombosis, which accounts for 80 to 85% of AV access loss. Treatment of venous stenosis by percutaneous angioplasty, endovascular stents and surgical revision is clinically important but many strategies to prevent thrombosis have been employed, such as antiplatelet agents, systemic anticoagulation, and experimental therapies as fish oils, heparinoids, clopidogrel, renin-angiotensin system antagonists, calcium channel blockers, alpha adrenergic antagonists, homocysteine-lowering agents and beta-hydroxybetamethyglutaryl coenzyme-A reductase inhibitors. Future but promising approaches are endovascular radiation and gene therapy.
UR - http://www.scopus.com/inward/record.url?scp=33749077325&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33749077325&partnerID=8YFLogxK
M3 - Article
VL - 19
SP - 280
EP - 285
JO - Journal of Nephrology
JF - Journal of Nephrology
SN - 1121-8428
IS - 3
ER -